Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study of R-CHOP Plus SYK Inhibitor TAK-659 for the Front-Line Treatment of High-Risk Diffuse Large B Cell Lymphoma (DLBCL)

NCT03742258 is registered in ClinicalTrials.gov with Northwestern University as lead sponsor.

NCT NCT03742258
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03742258 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study of R-CHOP Plus SYK Inhibitor TAK-659 for the Front-Line Treatment of High-Risk Diffuse Large B Cell Lymphoma (DLBCL)
Lead sponsor
Northwestern University
Phase
Phase 1
Overall status
Completed
Start date
March 13, 2019
Completion date
February 8, 2024
Enrollment
12 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse large b-cell lymphoma, diffuse large b-cell lymphoma activated b-cell type, diffuse large b-cell lymphoma germinal center b-cell type, diffuse large b-cell lymphoma, not otherwise specified, high grade b-cell lymphoma with myc and bcl2 and/or bcl6 rearrangements, high grade b-cell lymphoma, not otherwise specified, t-cell/histiocyte-rich large b-cell lymphoma